Cholecystitis in Villavicencio Hospitals

Sponsor
Hospital Departamental de Villavicencio (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06048575
Collaborator
Cooperative University of Colombia (Other), Clinica Primavera (Other)
1,500
2
17.1
750
44

Study Details

Study Description

Brief Summary

Background: Acute cholecystitis is a frequent cause of visits to the emergency ward. The complications of delays in attention and surgical therapy are substantial and should be considered to prevent them timely.

Objective: The study aims to evaluate the assistance provided to patients for cholecystitis in Villavicencio hospitals.

Methodology: A retrospective cross-sectional trial will be performed. The source of information will be the surgical database of hospitals at Villavicencio from 2019 to 2022. The records selected will be exported to an Excel spreadsheet for debugging and analysis. The central distribution and dispersion of numerical variables will be analyzed, as frequency and proportion of categorical variables with the software Prism 10.01.1 for Mac iOS. Chi-square and U-Mann & Whitney tests will compare variables according to the data type. A p<0.05 will be defined as statistically significant.

Expected results: the researchers hope to define the frequency of hospital discharges due to acute cholecystitis, the type of procedure performed, complications, and outcomes.

Conclusions: The research is feasible because the necessary information is available for evaluation, and it is helpful for the institutions and the region.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Cholecystectomy

Detailed Description

Biliary diseases are some leading causes of admission to emergency wards. Cholelithiasis and acute cholecystitis are prevalent in the Orinoquia region. Young and female populations are predominantly affected. Complications are prone to delayed definitive surgical therapy, which increases costs and the use of resources. Guidelines recommend early surgery during hospitalization for the first episode to minimize difficulties. There are limitations in the available technology recommended for treatment, especially in institutions dedicated to vulnerable populations. Laparoscopic cholecystectomy is the primary goal in cases required for gall bladder removal. Although the technology and trained personnel are available in local institutions, open procedures are still performed primarily, and restrictions are due to insurance coverage after more than 30 years of disseminating laparoscopic cholecystectomy worldwide.

It is necessary to know the prevalence of the disease and the therapy provided in general hospitals from the region to analyze associated factors with undesired results.

Determining the characteristics of patients admitted to hospitals by biliary pathology will provide essential information on the severity, care provided, definitive treatment, opportunity, and outcomes. Such an analysis will give knowledge to prioritize policies and resources, upgrade clinical practice guidelines, and improve early and long-term results.

Study Design

Study Type:
Observational
Anticipated Enrollment :
1500 participants
Observational Model:
Other
Time Perspective:
Retrospective
Official Title:
Characteristics of the Attention Provided to Patients With Cholecystitis in Villavicencio Hospitals, Colombia: A Retrospective Cross-sectional Trial.
Anticipated Study Start Date :
Jan 28, 2024
Anticipated Primary Completion Date :
Dec 31, 2024
Anticipated Study Completion Date :
Jun 30, 2025

Arms and Interventions

Arm Intervention/Treatment
Number of patients with early therapy

Patients with early surgery (<72 hours of admission).

Procedure: Cholecystectomy
Early or late surgery, ambulatory, emergency, or differed.

Number of patients with subacute therapy

Patients with surgery for three days or more.

Procedure: Cholecystectomy
Early or late surgery, ambulatory, emergency, or differed.

Number of patients with late therapy

Patients with surgery beyond ten days.

Procedure: Cholecystectomy
Early or late surgery, ambulatory, emergency, or differed.

Number of patients with no therapy

Patients discharged with no surgical therapy.

Procedure: Cholecystectomy
Early or late surgery, ambulatory, emergency, or differed.

Outcome Measures

Primary Outcome Measures

  1. Mortality [28 days]

    Number of patients deceased due to the biliary disease, complications, or other conditions.

Secondary Outcome Measures

  1. Hospital length of stay [28 days]

    Number of days before discharge.

  2. Need of ICU [28 days]

    Patients admitted to ICU under any circumstance.

  3. ICU length of stay [28 days]

    Number of days hospitalized in ICU

  4. Surgical site infection [28 days]

    Number of patients with infections associated with the procedure (superficial, deep, organ/space)

  5. Need of mechanical ventilation [28 days]

    Number of patients needing mechanical ventilation

  6. Complicated presentation [28 days]

    Number of patients with complications of the disease previous or during hospitalization, but not related to the surgical procedure

  7. Surgical complications [28 days]

    Number of patients with complications related to the surgical procedure

Eligibility Criteria

Criteria

Ages Eligible for Study:
16 Years to 120 Years
Sexes Eligible for Study:
All
Inclusion Criteria:
  • Patients admitted with acute or chronic biliary pathology.
Exclusion Criteria:
  • None.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Clinica Primavera Villavicencio Meta Colombia 50001
2 Hospital Departamental de Villavicencio Villavicencio Meta Colombia 50001

Sponsors and Collaborators

  • Hospital Departamental de Villavicencio
  • Cooperative University of Colombia
  • Clinica Primavera

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Norton Perez-Gutierrez, MD, Principal investigator, Hospital Departamental de Villavicencio
ClinicalTrials.gov Identifier:
NCT06048575
Other Study ID Numbers:
  • GRIVI_2023_04_Cholecystitis
First Posted:
Sep 21, 2023
Last Update Posted:
Sep 21, 2023
Last Verified:
Sep 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Norton Perez-Gutierrez, MD, Principal investigator, Hospital Departamental de Villavicencio
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 21, 2023